Capricor Therapeutics (CAPR) Short term Debt (2017)

Capricor Therapeutics' Short term Debt history runs 8 years deep, the most recent figure standing at $18628.0 for Q2 2023.

• In Q2 2023, Short term Debt fell 80.21% year-over-year to $18628.0; the TTM figure through Jun 2023 stood at $18628.0 (down 80.21% YoY), while the FY2022 annual figure was $89234.0, down 85.11% from the prior year.
• Short term Debt for Q2 2023 stood at $18628.0, roughly flat from $18716.0 in the prior quarter.
• The five-year high for Short term Debt was $599388.0 in Q4 2021, with the low at $18628.0 in Q2 2023.
• The 3-year median for Short term Debt is $89234.0 (2022), against an average of $211300.7.
• Peak annual rise in Short term Debt reached 80.21% in 2023, while the deepest fall reached 96.74% in 2023.
• Capricor Therapeutics' Short term Debt stood at $599388.0 in 2021, then plunged by 85.11% to $89234.0 in 2022, then sank by 79.12% to $18628.0 in 2023.
• Business Quant data shows CAPR's Short term Debt at $18628.0 in Q2 2023, $18716.0 in Q1 2023, and $89234.0 in Q4 2022.